NephroPlus Delivers Strong H1FY27 Performance Driven by International Expansion and Volume Growth
Nephrocare Health Services Ltd · Press Release · 03 Nov 2026, 11:48 pm
NephroPlus Delivers Strong H1FY27 Performance Driven by International Expansion and Volume Growth NephroPlus reported a 23.6% YoY rise in consolidated H1FY27 revenue to ₹585.2 crore, exceeding guidance, driven by a 12.6% YoY growth in treatments to 21.01 lakh and a 9.7% YoY increase in revenue per treatment to ₹2,785. Adjusted EBITDA rose 15.3% YoY to ₹134.4 crore, while Adjusted PAT surged 34.7% YoY to ₹76.1 crore with margins expanding 107 bps to 13.0%. For Q2FY27, revenue reached ₹303.4 crore, up 23.5% YoY. The network expanded to 570 clinics across six countries, with international markets contributing ~47% of revenue.
Original exchange filing (PDF)
More announcements from Nephrocare Health Services Ltd
- We hereby inform that the Company has approved grant of ESOPs under the Scheme as per the disclosure annexed herewith. · 17 Nov 2026
- Pursuant to Reg 30 of SEBI Listing Regulations, 2015, we hereby inform that the Company has approved allotment of 3,42,130 equity shares of Rs. 2/- each, pursuant to the exercise of stock .... · 17 Nov 2026
- Please find enclosed herewith Transcripts for the Investors Earnings call held on November 4, 2026. · 12 Nov 2026
- Pursuant to Reg 30 of the SEBI Listing Regulations, we hereby inform you that the Company has scheduled an investor conference call as per the disclosure annexed herewith. · 12 Nov 2026
- In Continuation to our letter dated October 21, 2026 please find enclosed link of the audio recording of the Investors'' Conference Call held on November 04, 2026 on the Unaudited Standalone .... · 04 Nov 2026
- Please find attached monitoring agency report for the quarter ended September 30, 2026. · 04 Nov 2026
- Please find investor presentation for quarter and half year ended September 30, 2026. · 03 Nov 2026
- Outcome of the Board meeting held on November 3, 2026 for considering and approving the financial results for the period ended September 30, 2026. · 03 Nov 2026
